Author

Markus F. Neurath

ONTAMALIMAB(-S) BLOCKS INFLAMMATORY BOWEL DISEASE T CELL ADHESION AND AMELIORATES T CELL-DEPENDENT COLITIS IN VIVO
ONTAMALIMAB(-S) BLOCKS INFLAMMATORY BOWEL DISEASE T CELL ADHESION AND AMELIORATES T CELL-DEPENDENT COLITIS IN VIVO

Markus F. Neurath  et al.

METHOD COMPARISON STUDY OF TWO COMMERCIALLY AVAILABLE TDM TEST FOR THE MEASUREMENT OF USTEKINUMAB LEVELS
METHOD COMPARISON STUDY OF TWO COMMERCIALLY AVAILABLE TDM TEST FOR THE MEASUREMENT OF USTEKINUMAB LEVELS

Markus F. Neurath  et al.

DOSE-DEPENDENT DIFFERENTIAL EFFECTS OF VEDOLIZUMAB THERAPY ON ADHESION OF REGULATORY AND EFFECTOR T CELLS
DOSE-DEPENDENT DIFFERENTIAL EFFECTS OF VEDOLIZUMAB THERAPY ON ADHESION OF REGULATORY AND EFFECTOR T CELLS

Markus F. Neurath  et al.

ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL
ADD-ON MULTIPLE SUBMUCOSAL INJECTIONS OF RNA OLIGONUCLEOTIDE GUT-1 TO TUMOR NECROSIS FACTOR-ANTAGONIST TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INVESTIGATOR-INITIATED TRIAL

Markus F. Neurath  et al.

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL
COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Markus F. Neurath  et al.

COMPUTER-AIDED DETECTION OF COLORECTAL POLYPS USING A NEWLY GENERATED DEEP CONVOLUTIONAL NEURAL NETWORK
COMPUTER-AIDED DETECTION OF COLORECTAL POLYPS USING A NEWLY GENERATED DEEP CONVOLUTIONAL NEURAL NETWORK

Markus F. Neurath  et al.

EXPERT CONSENSUS TO STANDARDISE TRANSCRIPTOME ANALYSIS IN INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS
EXPERT CONSENSUS TO STANDARDISE TRANSCRIPTOME ANALYSIS IN INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS

Markus F. Neurath  et al.

Item 1 - 7 / 7
1